Skip to Main Content Go to Sitemap
Profile picture for Dr. Theo Moraes

Theo Moraes

Title: Clinician Scientist, Translational Medicine
Designations: MD, PhD, FRCPC
Phone: 416-813-2196
Alternate Contact Name: Jennifer Courneyea
Alternate Phone: 416-813-7654 ext. 201153
Alternate Email:
U of T Positions: Associate Professor, Department of Paediatrics

Hospital Positions

Staff Physician, Respiratory Medicine


Dr. Theo Moraes graduated from medical school in 1997 (Toronto) and then completed his paediatric residency (Kingston) and paediatric respirology fellowship (Toronto) before pursuing his PhD in the laboratory of Dr. Gregory Downey and a postdoctoral fellowship with Dr. Tania Watts. His research focuses on respiratory epithelial biology, respiratory viruses, asthma and cystic fibrosis.

Moraes is the Toronto Site Director for the CHILD Cohort Study, a prospective longitudinal birth cohort study that aims to understand the genetic and environmental determinants of asthma and allergy. He is a member of the Program for Individualized CF Therapy (CFIT) which aims to advance personalised therapy in CF. His outpatient clinics include the Severe Asthma clinic, the Chronic Lung Disease of Prematurity clinic and the Aerodigestive clinic. He is a member of the Tobacco Action Committee at the American Thoracic Society and has a long-standing interest in advocacy around smoking and vaping cessation.


Theo Moraes is the site Director of the CHILD Study, a birth cohort involving almost 3,500 kids and their families. This study is helping us understand why some people get sick with different diseases including asthma and allergies. Moraes also runs a lab that studies lung epithelial cells; the cells that line the airways of our lungs. In this area he has projects focused on respiratory viruses, asthma, CF and vaping.

Education and experience

  • 1993–1997: MD, Doctor of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 
  • 19972000: Paediatrics Residency, Queen’s University, Kingston
  • 2000–2002: Paediatric Respirology Fellowship, SickKids, Toronto
  • 2003–2008: Staff Respirologist, (Part-time), SickKids, Toronto
  • 2002–2007: Doctorate, Doctor of Philosophy, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
  • 2007–2008: Postdoctoral Fellowship, Department of Immunology, University of Toronto, Toronto, Ontario, Canada
  • 2008–present: Staff Respirologist, SickKids


  • 2019: Dr. Melvin Wise Lecture in Pediatric Respirology. Montreal Children’s Hospital, Division of Respirology, Montreal, Quebec, Canada
  • 2018: Paul Man Lectureship, Alberta Respiratory Centre, University of Alberta, Edmonton, Alberta, Canada


  • May 2020–May 2021: Co-Principal Investigator. Rapid research in the CHILD Cohort to inform Canada's response to the COVID-19 pandemic: investigating the prevalence and predictors of SARS-CoV-2 infection, and the health and psychosocial impact of the COVID-19 pandemic on Canadian families. Op Grant: COVID-19 Rapid Research FO - Social Policy and Public Health Responses.
  • April 2020April 2021: Co-Investigator. Immune Responses to COVID-19: Correlates Across the Age Spectrum. Toronto COVID-19 Action Initiative. 
  • April 2020March 2024: Co-Investigator. Causational Roles of the Gut Microbiome in Childhood Asthma: Leveraging the CHILD Cohort Study. CIHR Team Grant: Canadian Microbiome Initiative 2: Research Teams.
  • Aug. 2019–Aug. 2021: Co-Principal Investigator. Does microbe infection influence nasal epithelial cell culture quality? 2019 Synergy Grants Competition.
  • July 2018–June 2023: Co-Investigator. Cell Therapy for Pulmonary Diseases.  National Sanitarium Association – Innovative Research Program.
  • May 2018–May 2020: Principal Investigator. Improving W1282X CFTR airway epithelial cell function with small molecules. Emily’s Entourage Catalyst for Cure Grant.
  • Jan. 2018–Jan. 2020: Co-Applicant. Personalized Therapy for Individuals with Cystic Fibrosis.  Genome Canada – LSARP.
  • Sept. 2017–Sept. 2020: Co-Applicant. Testing a novel approach to generate airway epithelial cells from induced pluripotent cell (iPSC) lines for CFTR functional assessment.  CF Canada – SickKids Program for Individualized CF Therapy: 2017 Synergy Grant Competition.   
Back to Top